Urethral Stricture Treatment Devices Market Report 2025

This Urethral Stricture Treatment Devices market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The urethral stricture treatment devices market size has grown strongly in recent years. It will grow from $1.37 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to factors such as the increasing prevalence of urethral strictures, a greater adoption of minimally invasive treatments, heightened awareness of urological disorders, rising healthcare expenditure in developed regions, and advancements in diagnostic capabilities.

The urethral stricture treatment devices market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The growth during the forecast period can be attributed to factors such as the rising demand for outpatient procedures, a growing focus on patient-centered care, the expansion of healthcare infrastructure in emerging markets, an increase in trauma-related strictures, and awareness campaigns led by healthcare organizations. Key trends in the forecast period include a shift toward minimally invasive surgeries, the integration of artificial intelligence (AI) in diagnostic tools, technological advancements in surgical devices, improvements in medical imaging techniques, and a focus on personalized treatment solutions.

The growing incidence of benign prostatic hyperplasia (BPH) and neurogenic bladder is expected to drive the growth of the urethral stricture treatment devices market. BPH is a common condition among older men, characterized by an enlarged prostate that can obstruct urinary flow and heighten the risk of urethral strictures. The rise in BPH cases is largely due to aging, with a higher frequency observed in men over 50, as well as factors such as lifestyle, hormonal changes, and chronic conditions. Urethral stricture treatment devices are often used in managing urological issues such as BPH, where complications such as post-surgical effects or prolonged catheterization may cause urethral narrowing. This may require the use of dilators, stents, or urethrotomy tools to restore proper urinary function. For example, a report from the Royal Pharmaceutical Society in September 2023 stated that approximately 3 million individuals in the UK are affected by BPH, with 50% of men aged 60-70 years and 90% of men over 80 years experiencing the condition. Therefore, the increasing prevalence of BPH and neurogenic bladder is expected to contribute to the growth of the urethral stricture treatment devices market.

Leading companies in the urethral stricture treatment devices market are pursuing strategic partnerships to improve technology integration and broaden their market presence. A strategic partnership involves two or more organizations working together, sharing resources and expertise to achieve mutual objectives. For example, in April 2024, Laborie Medical Technologies Corp., a US-based company specializing in diagnostic and therapeutic medical technologies, formed a partnership with the NHS Specialized Services Device Programme (SSDP). This collaboration enabled the inclusion of Laborie’s Optilume Urethral Drug-Coated Balloon (DCB) in the program, ensuring reimbursement for NHS hospitals in England and improving patient access to the device. Optilume combines balloon dilation with anti-proliferative drug delivery, offering a solution to reduce the recurrence of urethral strictures. This innovative, minimally invasive technology provides an alternative to traditional surgery or repeated treatments, addressing a significant need within the field of urology.

In October 2023, Laborie Medical Technologies Corp., a US-based company specializing in diagnostic and therapeutic medical technologies, acquired Urotronic Inc. for an undisclosed sum. This acquisition allows Laborie to incorporate Urotronic’s Optilume drug-coated balloon technology into its range of interventional urology solutions. The technology is designed to treat conditions such as urethral strictures and benign prostatic hyperplasia (BPH). Urotronic Inc. is a US-based medical device company focused on developing urethral stricture treatment devices and other urological treatment technologies.

Major players in the urethral stricture treatment devices market are Cardinal Health, Medtronic plc, Siemens Healthineers AG, Medline Industries LP., Becton Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, B. Braun SE, Olympus Corporation, Coloplast Ltd, Teleflex Incorporated, Karl Storz SE & Co. KG, Cook Medical, ConvaTec Inc., Ambu A/S, Richard Wolf GmbH, Laborie Medical Technologies, Bactiguard AB, UROMED Kurt Drews KG, Pnn Medical A/S, Hydrumedical SA, Allium Ltd., Med pro Medical B.V., Urotronic Inc., Rocamed SAM, and Zhejiang ChuangXiang Medical Technology Co. Ltd.

North America was the largest region in the urethral stricture treatment devices market in 2024. The regions covered in urethral stricture treatment devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the urethral stricture treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Urethral stricture treatment devices are medical tools designed to address urethral stricture, a condition where the urethra becomes narrowed, often causing urinary retention and difficulty with urination. These devices work to widen or bypass the constricted area of the urethra, restoring normal urine flow, and are used in both surgical and non-surgical treatment options.

The primary products in urethral stricture treatment devices include urethral dilators, urethral stents, urethral balloon dilation catheters, and urinary catheters. Urethral dilators are instruments used to gradually widen or stretch a narrowed urethra, facilitating easier urine flow. They are commonly used in procedures to treat urethral strictures by progressively increasing the diameter of the urethra. The strictures may be located in either the anterior or posterior sections, and the devices are typically used by end users such as hospitals, specialty clinics, and other healthcare facilities.

The urethral stricture treatment devices market research report is one of a series of new reports that provides urethral stricture treatment devices market statistics, including urethral stricture treatment devices industry global market size, regional shares, competitors with a urethral stricture treatment devices market share, detailed urethral stricture treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the urethral stricture treatment devices industry. This urethral stricture treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urethral stricture treatment devices market consists of sales of laser urethrotomy devices, biodegradable stents, lubricants, urethral calibration sets, and bougies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.